Oruka Therapeutics (NASDAQ:ORKA) Insider Joana Goncalves Sells 7,947 Shares of Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) insider Joana Goncalves sold 7,947 shares of the business’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $92.38, for a total value of $734,143.86. Following the completion of the sale, the insider directly owned 31,771 shares of the company’s stock, valued at $2,935,004.98. The trade was a 20.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Joana Goncalves also recently made the following trade(s):

• On Monday, August 17th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $111.84, for a total value of $782,880.00.

Oruka Therapeutics Stock Down 3.9%

NASDAQ:ORKA opened at $92.20 on Wednesday. The company has a market capitalization of $6.10 billion, a PE ratio of -45.42 and a beta of -0.34. Oruka Therapeutics, Inc. has a 52-week low of $14.66 and a 52-week high of $115.51. The stock’s 50 day moving average price is $95.87 and its 200 day moving average price is $72.78.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04). As a group, sell-side analysts anticipate that Oruka Therapeutics, Inc. will post -2.42 EPS for the current fiscal year.

Hedge Funds Weigh In On Oruka Therapeutics

A number of large investors have recently modified their holdings of ORKA. Engineers Gate Manager LP purchased a new position in shares of Oruka Therapeutics in the 2nd quarter valued at about $350,000. Arizona State Retirement System boosted its holdings in Oruka Therapeutics by 45.0% during the second quarter. Arizona State Retirement System now owns 8,671 shares of the company’s stock worth $825,000 after buying an additional 2,691 shares in the last quarter. Nykredit A S purchased a new stake in Oruka Therapeutics during the second quarter worth about $29,000. Braidwell LP purchased a new stake in Oruka Therapeutics during the second quarter worth about $26,473,000. Finally, Natural Investments LLC acquired a new position in Oruka Therapeutics during the second quarter worth about $202,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ORKA has been the subject of a number of research reports. BTIG Research reaffirmed a “buy” rating and issued a $151.00 target price on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Guggenheim reissued a “buy” rating and set a $200.00 price target on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Wall Street Zen cut Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. HC Wainwright reiterated a “buy” rating and issued a $120.00 target price on shares of Oruka Therapeutics in a research note on Thursday, September 3rd. Finally, Mizuho set a $120.00 target price on Oruka Therapeutics in a report on Thursday, September 3rd. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $133.00.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.